Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial.

Ngai, Lok Lam; Hanekamp, Diana; Janssen, Fleur; Carbaat-Ham, Jannemieke; Hofland, Maaike A M; Fayed, Mona M H E; Kelder, Angèle; Oudshoorn-van Marsbergen, Laura; Scholten, Willemijn J; Snel, Alexander N; Bachas, Costa; Tettero, Jesse M; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjorn T; Griskevicius, Laimonas; Juliusson, Gunnar; van de Loosdrecht, Arjan A; Maertens, Johan A; Manz, Markus G; ... (2023). Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. Blood, 141(21), pp. 2657-2661. American Society of Hematology 10.1182/blood.2022019160

[img] Text
blood.2022019160.pdf - Accepted Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Pabst, Thomas Niklaus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1528-0020

Publisher:

American Society of Hematology

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

18 Apr 2023 07:25

Last Modified:

26 May 2023 00:15

Publisher DOI:

10.1182/blood.2022019160

PubMed ID:

36898087

BORIS DOI:

10.48350/181793

URI:

https://boris.unibe.ch/id/eprint/181793

Actions (login required)

Edit item Edit item
Provide Feedback